Equities analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to report $0.05 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at $0.26. Sangamo Therapeutics reported earnings of ($0.23) per share during the same quarter last year, which would indicate a positive year over year growth rate of 121.7%. The business is expected to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that Sangamo Therapeutics will report full year earnings of $0.04 per share for the current fiscal year, with EPS estimates ranging from ($0.67) to $0.45. For the next year, analysts expect that the firm will post earnings of ($0.81) per share, with EPS estimates ranging from ($1.49) to ($0.21). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The business had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The company’s revenue for the quarter was up 46.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.14) EPS.
Several brokerages recently commented on SGMO. BidaskClub upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 17th. Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a research note on Wednesday, November 15th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, November 15th. Finally, Barclays reiterated a “buy” rating and set a $30.00 price target on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $20.50.
In related news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total transaction of $258,900.00. Following the sale, the vice president now directly owns 13,015 shares in the company, valued at approximately $224,638.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,403 shares of company stock worth $1,783,469. Insiders own 5.50% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in SGMO. New York State Common Retirement Fund boosted its holdings in Sangamo Therapeutics by 20.0% during the second quarter. New York State Common Retirement Fund now owns 76,200 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 12,699 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in Sangamo Therapeutics by 108.8% during the second quarter. UBS Asset Management Americas Inc. now owns 21,498 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 11,200 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Sangamo Therapeutics by 4.9% in the second quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after purchasing an additional 44,656 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after purchasing an additional 384,031 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in shares of Sangamo Therapeutics in the second quarter valued at about $124,000. 66.93% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sangamo Therapeutics (SGMO) traded up $0.30 during trading hours on Friday, reaching $25.70. 1,682,731 shares of the company traded hands, compared to its average volume of 2,129,296. Sangamo Therapeutics has a 12-month low of $3.85 and a 12-month high of $27.50. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.54 and a quick ratio of 5.64. The firm has a market cap of $2,210.00, a price-to-earnings ratio of -35.99 and a beta of 2.60.
TRADEMARK VIOLATION WARNING: “$0.05 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/03/14/0-05-earnings-per-share-expected-for-sangamo-therapeutics-inc-sgmo-this-quarter.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.